Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2009 1
2010 2
2011 4
2012 2
2013 2
2014 1
2015 1
2016 4
2017 3
2018 9
2019 13
2020 19
2021 18
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Garakani A, et al. Front Psychiatry. 2020 Dec 23;11:595584. doi: 10.3389/fpsyt.2020.595584. eCollection 2020. Front Psychiatry. 2020. PMID: 33424664 Free PMC article. Review.
Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. ...Posttraumatic stress disorder and obsessive-compulsive disorder are excluded from this review. ...
Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. ...Posttraumatic stress d
Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
Melas PA, Scherma M, Fratta W, Cifani C, Fadda P. Melas PA, et al. Int J Mol Sci. 2021 Feb 13;22(4):1863. doi: 10.3390/ijms22041863. Int J Mol Sci. 2021. PMID: 33668469 Free PMC article. Review.
Since CBD interacts with a wide variety of molecular targets in the brain, its therapeutic potential has been investigated in a number of neuropsychiatric diseases, including anxiety and mood disorders. Specifically, CBD has received growing attention due to its anx …
Since CBD interacts with a wide variety of molecular targets in the brain, its therapeutic potential has been investigated in a number of ne …
Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Bonaccorso S, et al. Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Neurotoxicology. 2019. PMID: 31412258 Review.
Cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. ...There is currently limited evidence regarding the safety and efficacy of CBD for the treatment of psychiatric disorders. However, availab
Cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. ...Ther
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis.
Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N. Gobbi G, et al. JAMA Psychiatry. 2019 Apr 1;76(4):426-434. doi: 10.1001/jamapsychiatry.2018.4500. JAMA Psychiatry. 2019. PMID: 30758486 Free PMC article.
While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact of cannabis use on mood and suicidality in young adulthood. OBJECTIVE: To provide a summary estimate of the extent to which cannabis …
While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact …
Cannabidiol for Mood Disorders: A Call for More Research.
Bartoli F, Bachi B, Calabrese A, Moretti F, Crocamo C, Carrà G. Bartoli F, et al. Can J Psychiatry. 2021 Feb;66(2):182-183. doi: 10.1177/0706743720926798. Epub 2020 May 14. Can J Psychiatry. 2021. PMID: 32406255 Free PMC article. No abstract available.
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Sarris J, et al. BMC Psychiatry. 2020 Jan 16;20(1):24. doi: 10.1186/s12888-019-2409-8. BMC Psychiatry. 2020. PMID: 31948424 Free PMC article.
METHODS: The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations and plant-derived cannabinoid isolates in mood, anxiety, …
METHODS: The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric diso
The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders.
Ferber SG, Namdar D, Hen-Shoval D, Eger G, Koltai H, Shoval G, Shbiro L, Weller A. Ferber SG, et al. Curr Neuropharmacol. 2020;18(2):87-96. doi: 10.2174/1570159X17666190903103923. Curr Neuropharmacol. 2020. PMID: 31481004 Free PMC article. Review.
Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood disorders present with treatment-resistant forms of depression, co-morbid anxiety, other psychiatric disorders and
Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from
Review of the neurological benefits of phytocannabinoids.
Maroon J, Bost J. Maroon J, et al. Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Surg Neurol Int. 2018. PMID: 29770251 Free PMC article. Review.
BACKGROUND: Numerous physical, psychological, and emotional benefits have been attributed to marijuana since its first reported use in 2,600 BC in a Chinese pharmacopoeia. The phytocannabinoids, cannabidiol (CBD), and delta-9-tetrahydrocannabinol (delta9-THC) are the most …
BACKGROUND: Numerous physical, psychological, and emotional benefits have been attributed to marijuana since its first reported use in 2,600 …
Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
Stanciu CN, Brunette MF, Teja N, Budney AJ. Stanciu CN, et al. Psychiatr Serv. 2021 Apr 1;72(4):429-436. doi: 10.1176/appi.ps.202000189. Epub 2021 Feb 3. Psychiatr Serv. 2021. PMID: 33530732 Free PMC article.
OBJECTIVE: Two primary compounds of the cannabis plant (Cannabis sativa), delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), differentially and dose-dependently affect mood and anxiety. In this systematic review, the authors summarize the design and results o …
OBJECTIVE: Two primary compounds of the cannabis plant (Cannabis sativa), delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), d …
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies.
Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, Grunstein RR, Hoyos CM. Suraev AS, et al. Sleep Med Rev. 2020 Oct;53:101339. doi: 10.1016/j.smrv.2020.101339. Epub 2020 May 16. Sleep Med Rev. 2020. PMID: 32603954
Cannabinoids, including the two main phytocannabinoids delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), are being increasingly utilised as pharmacological interventions for sleep disorders. THC and CBD are known to interact with the endocannabinoid and oth …
Cannabinoids, including the two main phytocannabinoids delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), are being increasin …
75 results